Stop Guessing.
Start Targeting
Because your cancer is as unique as your DNA, your treatment should be too.
Precision insights that complement standard oncology care to guide next-step planning and ongoing monitoring.
Why do I need this test if I already have a diagnosis?
Standard oncology often treats cancer based on where it started (the organ). But two people with lung cancer can have completely different biological drivers. Without a Personalised Cancer Plan, you are essentially fighting an invisible enemy. Our testing removes the blindfold, allowing your medical team to see exactly which ‘locks’ your cancer uses, so we can find the right ‘key’ to stop it.
What is Personalised Cancer Care
A Personalised Cancer Plan combines standard mainstream treatments with precision medicine to guide intelligent and individualized treatments.
In a published study, researchers observed encouraging results for patients receiving precision oncology compared with standard care.
In a published study comparing matched vs non-matched approaches:1,2
- Median overall survival: 11.4 vs 8.6 months
- Time without progression: 4.0 vs 2.8 months
- Tumor response observed in 27% vs 5% of patients
- Disease control reported in 70% vs 27%
Matching treatment to a patient’s cancer profile may be associated with more favorable outcomes.
Median overall survival (Months)1,2
m
m
therapy
therapy
Median progression-free survival (months)1,2
m
m
therapy
therapy
- Overall survival improved from 25.8 to 51.7 weeks
- Progression-free survival increased from 12.0 to 22.9 weeks
- Late-stage survival extended from approximately 6 months to over 15 months
- Disease control achieved in 41% of patients
Impact of Precision Oncology
Supporting clearer, more informed treatment decisions
Cancer treatment involves many important decisions guided by clinical evaluation, imaging, pathology, and established medical guidelines.
Advances in precision medicine allow doctors to understand cancer at a biological level, adding insight that may support treatment planning and monitoring.
To the family member searching for answers tonight..
Contact our Professional Team for Liquid Biopsy
What is your benefit?
To support improved treatment outcomes by helping identify treatments that may be more effective for your specific cancer — while helping minimise unnecessary side effects from less effective treatments.
A Personalised Cancer Plan
(CTCs) analysis
(ctDNA) profiling
Key findings from a published study:1,2
In patients with advanced cancer, around 4 out of 10 in a matched treatment group experienced tumor response or disease stabilization for a period of time.
(Comparing matched vs non-matched treatment approaches)
Treatment Choice May Influence Outcomes1,2
Higher tumor response was observed in patients receiving matched approaches compared to non-matched approaches in a published study.
1. Results observed in a published study. Individual outcomes may vary.
2. Source: Tsimberidou et al., 2014, Journal of Clinical Oncology (MD Anderson IMPACT study, n=1,144). Study conducted in advanced cancer patients comparing matched and non-matched approaches.
Genetic testing of tumors may help guide
more personalized treatment decisions1,2
1. Results observed in a published study. Individual outcomes may vary.
2. Source: Rosell et al., 2013; Lindeman et al., 2018.
Studies on molecular profiling in lung cancer, including the identification of actionable mutations in a subset of patients and its role in supporting treatment planning. Findings may vary depending on patient and testing approach.
Contact our Professional Team for Liquid Biopsy
What is your benefit?
To support improved treatment outcomes by helping identify treatments that may be more effective for your specific cancer — while helping minimise unnecessary side effects from less effective treatments.
References
Selected published studies and reviews relevant to precision medicine and biologically informed approaches in oncology.
| No. | Study Title / Citation | Year | Key Findings | Relevance |
|---|---|---|---|---|
| 1 |
Personalized medicine in a phase I clinical trials program: The MD Anderson Cancer Center initiative
Tsimberidou, A. M., Iskander, N. G., Hong, D. S., et al. (2014). Journal of Clinical Oncology, 32(8), 761–769.
|
2014 | Key findings Patients receiving matched therapies showed longer median overall survival (11.4 vs 8.6 months) and progression-free survival (4.0 vs 2.8 months) in this cohort. | Relevance Suggests that treatment matched to tumour biology may be associated with differences in outcomes in selected patients. |
| 2 |
Impact of precision medicine in diverse cancers: A meta-analysis of phase II clinical trials
Schwaederle, M., Zhao, M., Lee, J. J., et al. (2016). Journal of Clinical Oncology, 34(15), 1791–1799.
|
2016 | Key findings Higher response rates and longer progression-free survival were observed in patients treated with biomarker-matched therapies across pooled studies. | Relevance Indicates that biomarker-guided approaches may help inform treatment selection in certain settings. |
| 3 |
Pilot study using molecular profiling of patients’ tumors to find potential targets and select treatments for refractory cancers
Von Hoff, D. D., Stephenson, J. J., Rosen, P., et al. (2010). Journal of Clinical Oncology, 28(33), 4877–4883.
|
2010 | Key findings A proportion of patients experienced longer progression-free survival when treatment selection was guided by molecular profiling. | Relevance Suggests that profiling tumour characteristics may support more individualized treatment strategies. |
| 4 |
Cancer therapy directed by comprehensive genomic profiling: A single-center study
Wheler, J. J., Janku, F., Naing, A., et al. (2012). Cancer Research, 72(Suppl 8), 2776.
|
2012 | Key findings Some patients receiving matched therapies showed longer progression-free survival compared to prior treatments. | Relevance Highlights that integrating molecular data may provide additional insight for treatment planning. |
| 5 |
Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy
Alix-Panabières, C., & Pantel, K. (2016). Nature Reviews Clinical Oncology, 13(8), 479–491.
|
2016 | Key findings Liquid biopsy technologies provide information on tumour characteristics and disease monitoring across multiple cancer types. | Relevance Indicates that non-invasive testing approaches may offer additional biological information to support clinical decision-making. |
For educational purposes only. Findings are based on published studies. Outcomes may vary depending on tumour biology, stage, patient condition, and treatment context.
Contact Us
Contact Us for the updated information on Precision Medicine
+852 4750 3485
Email Us
info@mycancerinfo.org